Non-Alcoholic Fatty Pancreatic Disease: A Review of Literature - PubMed (original) (raw)

Review

Non-Alcoholic Fatty Pancreatic Disease: A Review of Literature

Hassan Tariq et al. Gastroenterology Res. 2016 Dec.

Abstract

There is an epidemic of obesity worldwide. The prevalence of obesity has doubled over the last three decades. Obesity, especially abdominal obesity is associated with insulin resistance that can lead to pancreatic steatosis and non-alcoholic fatty pancreatic disease (NAFPD). NAFPD describes a phenotype entity ranging from deposition of fat in the pancreas to pancreatic inflammation, and resultant fibrosis, which is similar to that of non-alcoholic fatty liver disease (NAFLD). NAFPD may represent a meaningful manifestation of metabolic syndrome. Pancreatic steatosis can be diagnosed on ultrasound, computed tomography (CT) scan or magnetic resonance imaging (MRI). In addition to a correlation between pancreatic steatosis and metabolic syndrome, pancreatic steatosis may lead to a worse outcome in pancreatitis and may be an etiological factor in pancreatic cancer, but we need further research to examine the associations, pathophysiology, and the impact of pancreatic steatosis and NAFPD on the human health.

Keywords: Metabolic syndrome; Non-alcoholic fatty pancreatic disease; Pancreatic steatosis.

PubMed Disclaimer

Similar articles

• Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review.
  Romana BS, Chela H, Dailey FE, Nassir F, Tahan V. Romana BS, et al. Endocr Metab Immune Disord Drug Targets. 2018;18(6):547-554. doi: 10.2174/1871530318666180328111302. Endocr Metab Immune Disord Drug Targets. 2018. PMID: 29595117 Review.
• Non-alcoholic fatty pancreas disease - practices for clinicians.
  Pinte L, Balaban DV, Băicuş C, Jinga M. Pinte L, et al. Rom J Intern Med. 2019 Sep 1;57(3):209-219. doi: 10.2478/rjim-2019-0005. Rom J Intern Med. 2019. PMID: 30901317 Review.
• Non-Alcoholic Fatty Pancreas Disease: The Unsung Disease.
  Sevim BC, Chela H, Ertugrul H, Malik LS, Malik S, Basar O, Daglilar E, Samiullah S, Gaballah AH, Tahan V. Sevim BC, et al. Endocr Metab Immune Disord Drug Targets. 2023;23(4):485-493. doi: 10.2174/1871530322666220929142905. Endocr Metab Immune Disord Drug Targets. 2023. PMID: 36177623
• [NON-ALCOHOLIC FATTY PANCREATIC DISEASE (NAFPD) AND THE METABOLIC SYNDROME: INITIATING FACTOR OR ADDITIONAL COMPONENT?].
  Grigorieva IN, Efimova OV, Tov NL, Suvorova TS. Grigorieva IN, et al. Eksp Klin Gastroenterol. 2015;(9):86-91. Eksp Klin Gastroenterol. 2015. PMID: 26931016 Review. Russian.
• [Lipid accumulation in the pancreas: clinical significance of NAFPD (non-alcoholic fatty pancreas disease)].
  Jermendy G. Jermendy G. Orv Hetil. 2022 Oct 30;163(44):1735-1742. doi: 10.1556/650.2022.32638. Print 2022 Oct 30. Orv Hetil. 2022. PMID: 36309887 Hungarian.

Cited by

• Prevalence of metabolic syndrome among adults treated at a district hospital outpatient department.
  Van Jaarsveldt C, Jabari T, Zwarts E, Färber S, Sikuza Y, Schilling H, Pauw S, Klein E, Van Rooyen C, Joubert G, Van der Bijl CC. Van Jaarsveldt C, et al. S Afr Fam Pract (2004). 2024 Sep 30;66(1):e1-e7. doi: 10.4102/safp.v66i1.5959. S Afr Fam Pract (2004). 2024. PMID: 39354791 Free PMC article.
• Research advances in the therapy of metabolic syndrome.
  Lin Z, Sun L. Lin Z, et al. Front Pharmacol. 2024 Jul 30;15:1364881. doi: 10.3389/fphar.2024.1364881. eCollection 2024. Front Pharmacol. 2024. PMID: 39139641 Free PMC article. Review.
• Lifestyle Medicine for the Prevention and Treatment of Pancreatitis and Pancreatic Cancer.
  Subramanian SK, Brahmbhatt B, Bailey-Lundberg JM, Thosani NC, Mutha P. Subramanian SK, et al. Diagnostics (Basel). 2024 Mar 14;14(6):614. doi: 10.3390/diagnostics14060614. Diagnostics (Basel). 2024. PMID: 38535034 Free PMC article. Review.
• Pancreatic index: A prognostic factor of upfront surgery for body or tail pancreatic ductal adenocarcinoma with vascular involvement-A retrospective study.
  Qian L, Li J, Sun Y, Chai W, Deng X, Wang W, Shen B. Qian L, et al. Cancer Med. 2023 Dec;12(23):21199-21208. doi: 10.1002/cam4.6687. Epub 2023 Nov 7. Cancer Med. 2023. PMID: 37933476 Free PMC article.
• Fatty Pancreas Is a Risk Factor for Pancreatic Cancer: A Systematic Review and Meta-Analysis of 2956 Patients.
  Lipp M, Tarján D, Lee J, Zolcsák Á, Szalai E, Teutsch B, Faluhelyi N, Erőss B, Hegyi P, Mikó A. Lipp M, et al. Cancers (Basel). 2023 Oct 7;15(19):4876. doi: 10.3390/cancers15194876. Cancers (Basel). 2023. PMID: 37835570 Free PMC article. Review.

References

1. 1. WHO. Controlling the global obesity epidemic, 2003. available from URL: http://www.who.int/nutrition/topics/obesity/en/.
2. 1. WHO. Obesity and overweight, 2015. available from: URL: http://www.who.int/mediacentre/factsheets/fs311/en/.
3. 1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806–814. doi: 10.1001/jama.2014.732. - DOI - PMC - PubMed
4. 1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–781. doi: 10.1016/S0140-6736(14)60460-8. - DOI - PMC - PubMed
5. 1. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378(9793):804–814. doi: 10.1016/S0140-6736(11)60813-1. - DOI - PubMed

Publication types

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • scite Smart Citations